Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) Income towards Parent Company (2022 - 2025)

Envoy Medical's Income towards Parent Company history spans 4 years, with the latest figure at -$6.2 million for Q3 2025.

  • For Q3 2025, Income towards Parent Company fell 17.96% year-over-year to -$6.2 million; the TTM value through Sep 2025 reached -$22.4 million, up 14.69%, while the annual FY2024 figure was -$20.1 million, 9.26% down from the prior year.
  • Income towards Parent Company for Q3 2025 was -$6.2 million at Envoy Medical, down from -$5.7 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $12.5 million in Q1 2022 and bottomed at -$11.1 million in Q4 2023.
  • The 4-year median for Income towards Parent Company is -$4.9 million (2024), against an average of -$2.2 million.
  • The largest YoY upside for Income towards Parent Company was 55.62% in 2024 against a maximum downside of 785.52% in 2024.
  • A 4-year view of Income towards Parent Company shows it stood at -$2.0 million in 2022, then crashed by 453.4% to -$11.1 million in 2023, then skyrocketed by 55.62% to -$4.9 million in 2024, then decreased by 25.26% to -$6.2 million in 2025.
  • Per Business Quant, the three most recent readings for COCH's Income towards Parent Company are -$6.2 million (Q3 2025), -$5.7 million (Q2 2025), and -$5.6 million (Q1 2025).